9 results  1 of 1 

1 A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
Hyung Jun Kim, Sang Youn Hwang, Jung Woo Im, Ki Jeong Jeon, Wan Jeon
J Liver Cancer.2023;23(1):213-218.   Published online 2023 March 9     DOI: http://dx.doi.org/10.17998/jlc.2023.02.23
      
2 Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
Hongsik Kim, Byong Chang Jeong, Joohyun Hong, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Wan Song, Hyun Hwan Sung, Jung Yong Hong, Se Hoon Park
Cancer Res Treat.2023;55(2):636-642.   Published online 2022 October 6     DOI: http://dx.doi.org/10.4143/crt.2022.343
      
3 Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report
Ji Eun Han, Hyo Jung Cho, Soon Sun Kim, Jae Youn Cheong
J Liver Cancer.2021;21(2):169-176.   Published online 2021 September 30     DOI: http://dx.doi.org/10.17998/jlc.2021.08.26
      
4 Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Jwa Hoon Kim, Bokyung Ahn, Seung-Mo Hong, Hwoon-Yong Jung, Do Hoon Kim, Kee Don Choi, Ji Yong Ahn, Jeong Hoon Lee, Hee Kyoung Na, Jong Hoon Kim, Yong-Hee Kim, Hyeong Ryul Kim, Hyun Joo Lee, Sung-Bae Kim, Sook Ryun Park
Cancer Res Treat.2022;54(2):505-516.   Published online 2021 June 23     DOI: http://dx.doi.org/10.4143/crt.2020.1198
      
5 Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study
Joon Young Hur, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim
Blood Res.2020;55(2):85-90.   Published online 2020 June 30     DOI: http://dx.doi.org/10.5045/br.2020.2020014
      
6 Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
Jaewoong Kim, Jin Won Chang, Jun Yong Park
J Liver Cancer.2020;20(1):72-77.   Published online 2020 March 31     DOI: http://dx.doi.org/10.17998/jlc.20.1.72
      
7 Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy
Ye Jin Lee, Hak Tae Kim, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Jee Ho Choi, Woo Jin Lee
J Korean Med Sci.2019;34(26):e186.  Published online 2019 June 17     DOI: http://dx.doi.org/10.3346/jkms.2019.34.e186
   
8 A Case of Achieving Partial Remission with the Combination of Sorafenib and Nivolumab in a Patient with Hepatocellular Carcinoma Showing Disease Progression after Nivolumab Therapy
Sang Youn Hwang, Seon-Mi Lee, Jung Woo Im, Ki Jeong Jeon, Cheol-Won Choi, Kyung-Su Kim, Wan Jeon
J Liver Cancer.2019;19(1):74-78.   Published online 2019 March 31     DOI: http://dx.doi.org/10.17998/jlc.19.1.74
      
9 Increased Infiltration of CD8+ T Cells by Dacarbazine in a Patient with Mucosal Penile Melanoma Refractory to Nivolumab
Masato Funazumi, Takeshi Namiki, Yumi Arima, Kohei Kato, Kohei Nojima, Kentaro Tanaka, Keiko Miura, Hiroo Yokozeki
Ann Dermatol.2016;28(4):486-490.   Published online 2016 July 26     DOI: http://dx.doi.org/10.5021/ad.2016.28.4.486
      

 1 of 1